The variety of strict safety recommendations from the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee could have the unintended consequence of limiting access to Valeant Pharmaceuticals International Inc.’s plaque psoriasis candidate Siliq (brodalumab), should it reach the market.
Although all 18 panelists recommended the treatment for approval, several said they would only support the FDA’s backing if the...






